DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin in
combination with Pertuzumab with or without Toripalimab neoadjuvant therapy in patients with
HER2-positive breast cancer.